Josep Grinyo

Summary

Publications

  1. ncbi Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress
    Josep M Grinyo
    Nephrology Department, Hospital Univeritari de Bellvitge, IDIBELL, University of Barcelona, L Hospitalet de Llobregat, Barcelona, Spain
    Am J Transplant 9:2447-52. 2009
  2. ncbi Belatacept utilization recommendations: an expert position
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Department of Nephrology, Feixa Llarga, S N, 08907 Hospitalet de Llobregat, Barcelona, Spain
    Expert Opin Drug Saf 12:111-22. 2013
  3. ncbi Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study
    Josep Grinyo
    University Hospital of Bellvitge, Barcelona, Spain
    Transpl Int 25:1059-64. 2012
  4. ncbi Immunosuppression in the era of biological agents
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Universidad de Barcelona, Spain
    Adv Exp Med Biol 741:60-72. 2012
  5. ncbi The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Barcelona, Spain
    Nephrol Dial Transplant 24:2269-76. 2009
  6. ncbi An integrated safety profile analysis of belatacept in kidney transplant recipients
    Josep Grinyo
    Division of Nephrology, University Hospital of Bellvitge, Barcelona, Spain
    Transplantation 90:1521-7. 2010
  7. ncbi Optimal immunosuppression to prevent chronic allograft dysfunction
    Josep M Grinyo
    Department of Nephrology, Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL, Barcelona, Spain
    Kidney Int 78:S66-70. 2010
  8. ncbi Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients
    Josep M Grinyo
    Department of Nephrology, Hospital Universitari de Bellvitge, IDIBELL, LHospitalet de Llobregat, Barcelona, Spain
    Nephrol Dial Transplant 26:3750-5. 2011
  9. ncbi Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial
    Julio Pascual
    Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain
    Transplantation 89:994-1000. 2010
  10. ncbi Association of four DNA polymorphisms with acute rejection after kidney transplantation
    Josep Grinyo
    Department of Nephrology, Hospital de Bellvitge, University of Barcelona, Barcelona, Spain
    Transpl Int 21:879-91. 2008

Collaborators

Detail Information

Publications45

  1. ncbi Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress
    Josep M Grinyo
    Nephrology Department, Hospital Univeritari de Bellvitge, IDIBELL, University of Barcelona, L Hospitalet de Llobregat, Barcelona, Spain
    Am J Transplant 9:2447-52. 2009
    ..Meanwhile, the assessment of immunological risk by new monitoring tools could be a prerequisite to further implement such CNI sparing strategies...
  2. ncbi Belatacept utilization recommendations: an expert position
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Department of Nephrology, Feixa Llarga, S N, 08907 Hospitalet de Llobregat, Barcelona, Spain
    Expert Opin Drug Saf 12:111-22. 2013
    ..Future studies will clarify the optimal regimen for belatacept usage...
  3. ncbi Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study
    Josep Grinyo
    University Hospital of Bellvitge, Barcelona, Spain
    Transpl Int 25:1059-64. 2012
    ..Switching to a belatacept-based regimen from a CNI-based regimen resulted in a continued trend toward improved renal function at 2 years after switching...
  4. ncbi Immunosuppression in the era of biological agents
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Universidad de Barcelona, Spain
    Adv Exp Med Biol 741:60-72. 2012
    ..The majority of these new immunosuppressive agents are polyclonal or monoclonal antibodies and recently the so-called fusion proteins may be the start of a new era of biological immunosuppression for maintenance regimens...
  5. ncbi The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy
    Josep M Grinyo
    Hospital Universitari de Bellvitge, Barcelona, Spain
    Nephrol Dial Transplant 24:2269-76. 2009
    ..Exposure to mycophenolic acid (MPA), the primary active metabolite of mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies depending on the concomitantly administered immunosuppressive drugs...
  6. ncbi An integrated safety profile analysis of belatacept in kidney transplant recipients
    Josep Grinyo
    Division of Nephrology, University Hospital of Bellvitge, Barcelona, Spain
    Transplantation 90:1521-7. 2010
    ..The current analysis examined pooled safety data for belatacept versus cyclosporine used in combination with basiliximab, mycophenolate mofetil, and steroids...
  7. ncbi Optimal immunosuppression to prevent chronic allograft dysfunction
    Josep M Grinyo
    Department of Nephrology, Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL, Barcelona, Spain
    Kidney Int 78:S66-70. 2010
    ..Importantly, in any case, longer-term analyses of all these CNI-avoidance strategies are warranted in order to confirm whether persistent immune-mediated graft damage can be safely overcome...
  8. ncbi Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients
    Josep M Grinyo
    Department of Nephrology, Hospital Universitari de Bellvitge, IDIBELL, LHospitalet de Llobregat, Barcelona, Spain
    Nephrol Dial Transplant 26:3750-5. 2011
    ..Current knowledge about the natural history, treatment and physicians' perception of chronic allograft nephropathy (CAN) is limited. The present study evaluated the prevalence and determinants of CAN in renal transplant patients...
  9. ncbi Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial
    Julio Pascual
    Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain
    Transplantation 89:994-1000. 2010
    ..Clinical data are lacking concerning therapeutic action and systemic exposure of tacrolimus (TAC) and everolimus (EVL) in a combined regimen in renal transplantation...
  10. ncbi Association of four DNA polymorphisms with acute rejection after kidney transplantation
    Josep Grinyo
    Department of Nephrology, Hospital de Bellvitge, University of Barcelona, Barcelona, Spain
    Transpl Int 21:879-91. 2008
    ..Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant...
  11. ncbi Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats
    Nuria Lloberas
    Laboratory of Nephrology, Department of Medicine, University of Barcelona, Spain
    Nephrol Dial Transplant 23:3111-9. 2008
    ..We aimed to analyse the functional and histological profiles of damage and to define the contribution of inflammatory and pro-fibrotic mediators in the association of cyclosporine (CsA) and/or tacrolimus (Tac) with sirolimus (SRL)...
  12. ncbi New immunosuppressive protocols with the advent of novel biological drugs
    Josep M Cruzado
    Servei de Nefrologia, Hospital Universitari de Bellvitge, IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Transplantation 88:S20-3. 2009
    ..Perhaps, association of T-cell depleting agents with CD40-CD40L blockade may avoid both cellular rejection and, more interestingly, human leukocyte antigen sensitization...
  13. ncbi Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years
    Josep M Grinyo
    Nephrology Department, Hospital of Bellvitge, CSUB, Feixa Llarga s n, L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Transpl Int 16:820-7. 2003
    ..Starting MMF at low dose, MPA monitoring and probably CMV prophylaxis may improve the results of this regimen...
  14. ncbi Steroid or calcineurin inhibitor-sparing immunosuppressive protocols
    Josep M Grinyo
    Servei de Nefrologia, Hospital Universitari de Bellvitge, University of Barcelona, c Feixa Llarga s n, L Hospitalet, Barcelona, Spain
    Contrib Nephrol 146:30-42. 2005
    ....
  15. ncbi Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability?
    Oriol Bestard
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    Drugs 66:403-14. 2006
    ..Long-term follow-up studies must be performed to confirm the encouraging short-term data...
  16. ncbi Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients
    Federico Oppenheimer
    Hospital Clinico y Provincial de Barcelona, Barcelona, Spain
    Transplantation 83:645-8. 2007
    ..The absence of any clinically significant effect of FTY720 on cardiac rhythm demonstrates that the reduction in HR seen after the first dose does not persist in the maintenance phase...
  17. ncbi Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus
    Jose M Morales
    Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
    Transplantation 86:620-2. 2008
    ..009). Tacrolimus withdrawal from a combination of sirolimus and tacrolimus, in selected patients, may be observed at 2 years by an improvement in renal function and blood pressure without a higher incidence of proteinuria...
  18. ncbi Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies
    Josep M Cruzado
    Nephrology Department, Hospital Universitari de Bellvitge, IDIBELL, Feixa Llarga s n, L Hospitalet de Llobregat, Barcelona, Spain
    Contrib Nephrol 162:117-28. 2009
    ..Interference of CD40 by siRNA technology is able to induce a protective phenotype (anti-inflammatory, anti-apoptotic, anticoagulant) in endothelial cells in conjunction with fully avoidance of adaptative humoral immunity in the host...
  19. ncbi Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results
    Inés Rama
    Nephrology Department, Hospital Universitari de Bellvitge, Department of Medicine, University of Barcelona, L Hospitalet de Llobregat, Barcelona, Spain
    Transplantation 80:164-8. 2005
    ..Discontinuation of steroids has long been a goal of transplant teams. However, whether this strategy is associated or not with a higher risk of long-term graft loss has not been resolved...
  20. ncbi Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients
    Daniel Seron
    Department of Nephrology, Hospital Universitari de Bellvitge, Barcelona, Spain
    Transplantation 83:649-52. 2007
    ..T lymphocytes and macrophages interstitial infiltration was reduced in tacrolimus treated patients evaluated with protocol biopsies in comparison to cyclosporine-treated patients...
  21. ncbi Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft
    Oriol Bestard
    Department of Nephrology, Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
    Nephrol Dial Transplant 21:2320-4. 2006
  22. ncbi Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts
    Josep M Grinyo
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    Transplantation 78:1400-3. 2004
    ..Thus, our results suggest that MMF could be synergistic with the pharmacodynamic effect of low CsA in maintenance immunosuppression...
  23. ncbi Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates
    Oriol Bestard
    Department of Nephrology, Hospital de Bellvitge, Barcelona, Spain
    J Immunol 179:4901-9. 2007
    ..In conclusion, reaching donor-specific hyporesponsiveness is feasible after renal transplantation and associated with Treg recruitment in the graft...
  24. ncbi The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats
    Maria Flaquer
    Departament de Ciències Fisiològiques II, IDIBELL, University of Barcelona, Bellvitge Hospital, Spain
    Life Sci 87:147-53. 2010
    ..The purpose of this study was to evaluate the potential synergistic effect of this combination on diabetic kidney disease in rats...
  25. ncbi Baseline immunosuppression is associated with histological findings in early protocol biopsies
    Francesc Moreso
    Nephrology Department, Hospital Universitari de Bellvitge, c Feixa Llarga s n, 08907 L Hospitalet, Barcelona, Spain
    Transplantation 78:1064-8. 2004
    ..However, the utility of protocol biopsies to manage baseline immunosuppression has not been well characterized...
  26. ncbi Inhibitors of the mammalian target of rapamycin and transplant tolerance
    Oriol Bestard
    Nephrology Department, Renal Transplant Unit, Hospital Universitari de Bellvitge, Barcelona, Spain
    Transplantation 87:S27-9. 2009
    ..Here, we discuss and analyze the main mechanisms by which sirolimus may modulate the alloimmune response, thus facilitating a protolerogenic state in renal transplantation...
  27. ncbi Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study
    Jose Ballarin
    Nephrology Department of Fundació Puigvert, Hospital Universitari de Bellvitge, Spain
    Nephrol Dial Transplant 22:3196-201. 2007
    ..Membranous nephropathy is a common cause of nephrotic syndrome (NS) in adults. Its treatment is still under debate...
  28. ncbi Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients
    Oriol Bestard
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Am Soc Nephrol 19:1419-29. 2008
    ..Assessment of alloreactive memory/effector T cells might be helpful to tailor individual immunosuppression regimens for transplant recipients in the future...
  29. ncbi Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats
    Nuria Lloberas
    Nephrology Service, Hospital Universitari de Bellvitge, Feixa Llarga s n, 08907 L Hospitalet de Llobregat, Catalonia, Spain
    J Am Soc Nephrol 17:1395-404. 2006
    ..In conclusion, mTOR blockade by low-dose SRL has a beneficial effect in diabetic kidney disease, suggesting that the mTOR pathway has an important pathogenic role in diabetic nephropathy...
  30. ncbi Biomarkers in renal transplantation
    Oriol Bestard
    Renal Transplant Unit, Nephrology Department, Hospital Universitari de Bellvitge, Feixa Llarga s n, Barcelona, Spain
    Curr Opin Organ Transplant 15:467-73. 2010
    ..Here, we review recent important biomarkers that have shown relevant impact on renal graft outcome...
  31. ncbi Early hematopoietic microchimerism predicts clinical outcome after kidney transplantation
    Josep Maria Pujal
    Alloreactivity Unit, Translational Research Laboratory, Institut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, Spain
    Transplantation 84:1103-11. 2007
    ..This study aims to assess the rate of microchimerism after kidney transplantation and determine its influence on acute rejection in a 4-year follow-up...
  32. ncbi Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection
    Miguel Hueso
    Departament de Nefrologia, Hospital Universitari de Bellvitge IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Am J Pathol 176:1696-704. 2010
    ..These results suggest that the up-regulation of the IL-10 gene expression, as well as an increased proportion of B-lymphocytes in the inflammatory infiltrates, might be useful as markers of early chronic lesions in grafts with SCR...
  33. ncbi Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts
    Oriol Bestard
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Am Soc Nephrol 19:2020-6. 2008
    ....
  34. ncbi Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy
    Immaculada Herrero-Fresneda
    Laboratory of Experimental Nephrology, Department of Medicine, Universitat de Barcelona, Hospital Universitari de Bellvitge, Barcelona, Spain
    Transplantation 79:165-73. 2005
    ..Severe CAN may be prevented by reducing cold ischemia or strengthening immunosuppression. Because the former approach is not always possible, reinforcement of early immunosuppression constitutes an excellent alternative...
  35. ncbi Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
    Juan Torras
    Laboratory of Experimental Nephrology, Department of Medicine, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
    Nephrol Dial Transplant 24:3632-40. 2009
    ..In contrast, there are studies showing a nephro-protective effect of rapamycin in proteinuric diseases characterized by progressive interstitial inflammatory fibrosis...
  36. ncbi CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling
    Raquel Pluvinet
    Medical and Molecular Genetics Center, Institut d Investigació Biomèdica de Bellvitge IDIBELL, Hospital Duran i Reynals, L Hospitalet de Llobregat, Barcelona, Spain
    Blood 112:3624-37. 2008
    ..Our study also highlights the anti-inflammatory potential of RNAi-mediated CD40 inhibition, and the relevance of CD40 signaling for therapeutic intervention...
  37. ncbi Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome
    Augusto Vallejos
    Department of Nephrology, Hospital Universitari Bellvitge, C/Feixa Llarga s/n, L'Hospitalet, 08907 Barcelona, Spain
    Nephrol Dial Transplant 20:2511-6. 2005
    ..Our results indicate that histology may be superior to RI in predicting graft function deterioration, at least in patients with stable renal function...
  38. ncbi Glomerular enlargement assessed by paired donor and early protocol renal allograft biopsies
    Gabriela Alperovich
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    Am J Transplant 4:650-4. 2004
    ..Glomerular enlargement is impaired in patients with chronic allograft nephropathy...
  39. ncbi Structural and functional correlations in stable renal allografts
    Xavier Fulladosa
    Nephrology Department, Hospital de Bellvitge, Universitat de Barcelona, L Hospitalet, Barcelona, Spain
    Am J Kidney Dis 41:1065-73. 2003
    ..Thus, we used early protocol biopsies to analyze structural and functional correlations in stable grafts...
  40. ncbi Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance
    Josep M Cruzado
    Nephrology Department, Hospital de Bellvitge, Department of Medicine, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
    Am J Transplant 3:357-60. 2003
    ..Our results suggest that the indication for pretransplant interferon should be extended to treat all HCV-RNA positive candidates for renal transplantation...
  41. ncbi Estimation of total glomerular number in stable renal transplants
    Xavier Fulladosa
    Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Am Soc Nephrol 14:2662-8. 2003
    ..01) and the lower N(g)-W&G (r = -0.40, P = 0.01). Total glomerular number can be estimated in stable renal allografts by means of a renal biopsy and MRI. Our data show that N(g) depends on donor age and positively correlates with GFR...
  42. ncbi Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies
    Daniel Seron
    Nephrology and Pathology Departments, Hospital de Bellvitge, Universitat de Barcelona, L Hospitalet, Barcelona, Spain
    Kidney Int 61:727-33. 2002
    ..Although the presence of CAN in protocol renal biopsies is a predictor of outcome, the reliability of this diagnosis according to Banff criteria has not been characterized...
  43. ncbi Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation
    Meritxell Ibernon
    Nephrology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Transplantation 88:272-8. 2009
    ..We evaluate the relationship among serum mannose-binding lectin (MBL), chronic inflammation, NODAT, and infection...
  44. ncbi The renin angiotensin system blockade in kidney transplantation: pros and cons
    Josep M Cruzado
    Servei de Nefrologia, Hospital Universitari de Bellvitge, IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Transpl Int 21:304-13. 2008
    ..Meanwhile, we should empirically balance case to case the pros and cons of RAS blockade in renal transplantation...
  45. ncbi Different storing and processing conditions of human lymphocytes do not alter P-glycoprotein rhodamine 123 efflux
    Gemma Chiva-Blanch
    Nephrology Department, IDIBELL Hospital Universitari Bellvitge, L Hospitalet de Llobregat, Catalonia, Spain
    J Pharm Pharm Sci 12:357-66. 2009
    ..These results allow standardization of Pgp activity measurement in different individuals with different timing of blood sampling and in different geographic areas...